Education
Learn biotech investing
Free, plain-English guides for investors who can read a balance sheet but not a Kaplan–Meier curve. Work through them in order, or jump to the one that matches the decision in front of you.
Start here
The vocabulary and the mechanics. No prior clinical background assumed.
Clinical Trial Phases Explained
What Phase 1, 2, and 3 trials mean, success rates at each phase, and what investors should expect. Plain-English analysis for biotech investors from ClinicalInvestor.
Read guide →
The FDA Approval Process Explained
Step-by-step guide to how drugs get approved in the US, timelines, and what each stage means for investors.
Read guide →
How to Invest in Biotech Stocks: Everything You Need to Know
Learn how to invest in biotech stocks from scratch. Understand clinical trials, catalysts, risk management, and how to evaluate pipeline companies. Plain-English guide.
Read guide →
What Is a PDUFA Date? Everything Biotech Investors Need to Know
Learn what PDUFA dates are, why they move biotech stocks 20-60%, how to find upcoming PDUFA dates, and proven strategies for trading them. Plain-English guide.
Read guide →
Understanding Cash Runway in Biotech Stocks
How to calculate a biotech company's cash runway, why it matters more than revenue, and how it predicts dilution risk.
Read guide →
What Is an FDA Clinical Hold?
What triggers an FDA clinical hold, how long they typically last, and what it means for a biotech stock when a trial is paused.
Read guide →
Read the data
Endpoints, trial design, and the questions a press release is written to avoid.
Biotech Dilution and Secondary Offerings Explained
Why clinical-stage biotechs raise capital through secondary offerings, how dilution affects existing shareholders, and how to evaluate offering terms.
Read guide →
Risk Management for Biotech Investors
Position sizing, binary events, portfolio allocation, and stop-loss strategies for volatile biotech stocks.
Read guide →
Biotech Catalyst Trading: Proven Strategies for Binary Events
How biotech investors approach catalysts such as PDUFA dates, Phase 3 readouts and AdCom votes: position sizing, risk management and timing, explained.
Read guide →
GLP-1 and Obesity Drugs: Investor Guide
The GLP-1 revolution explained — market size, key players, pipeline drugs, and investment thesis for the obesity drug market.
Read guide →
How to Read a 10-K for Biotech Companies
What matters in a clinical-stage biotech 10-K — cash runway, R&D spend, going-concern language, and red flags investors miss.
Read guide →
How to Read Clinical Trial Data: A Plain-English Guide for Investors
How to read clinical trial results as an investor: endpoints, p-values, hazard ratios and safety data, and what they mean for a biotech stock.
Read guide →
Understanding Biotech Company Financials
Cash runway, burn rate, dilution risk, and key financial metrics for pre-revenue biotech companies. Plain-English analysis for biotech investors from ClinicalInvestor.
Read guide →
Understanding Clinical Trial Endpoints: What Biotech Investors Need to Know
Primary vs. secondary endpoints, surrogate vs. clinical endpoints, and how to judge whether a trial result is meaningful before you invest in a biotech stock.
Read guide →
Trade the catalyst
Position sizing around binary events, and what the market prices in beforehand.
New guides in your inbox
The free Sunday briefing includes new guides as they publish, plus the catalysts landing that week. No card required, unsubscribe any time.
Free weekly biotech briefing. No spam. We only use this address for the briefing. By subscribing, you agree to our Privacy Policy and Terms.